Mandate

Vinge advises on division of Creades

January 24, 2013

On the initiative of the majority shareholders, Bioinvestor and Pan Capital, it is proposed that Creades (NASDAQ OMX First North) will be divided into two companies pursuant to a squeeze out procedure whereby 30 per cent of Creades’ net worth will be transferred to a new, unlisted company, Sedarec, which will be distributed to the shareholders in the manner desired by them. Pan Capital will become the majority shareholder in Sedarec which, following completion of the squeeze out procedure, will be liquidated under Pan Capital’s management, whereas Creades, with Bioinvestor as its majority shareholder, will continue its long-term strategy.

Vinge team advising Creades primarily consisted of partner Erik Sjöman and associate Jo-Anna Nordström.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024